Conference item : Abstract

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Morgensztern, D., Govindan, R., Cobo, M., Ponce Aix, S., Postmus, P. E., Lewanski, C., Bennouna, J., Fischer, J., Juan-Vidal, O., Stewart, D., Ardizzoni, A., Bhore, R., Wolfsteiner, M., Reck, M., Talbot, D., & Ong, T. J. (2018). Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+). Journal of Thoracic Oncology, 13(10), S489–S489.

MLA Style

Morgensztern, D., et al. “Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+).” Journal of Thoracic Oncology, vol. 13, no. 10, Elsevier, 2018, pp. S489–S489.

Chicago Style

Morgensztern, D, R Govindan, M Cobo, S Ponce Aix, PE Postmus, C Lewanski, J Bennouna, et al. 2018. “Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+).” In Journal of Thoracic Oncology, 13:S489–S489. Elsevier.
Tweet
Print

Access Document

Publisher copy:: 10.1016/j.jtho.2018.08.626

Authors

+ Morgensztern, D More by this author

Role:

Author

+ Govindan, R More by this author

Role:

Author

+ Cobo, M More by this author

Role:

Author

+ Ponce Aix, S More by this author

Role:

Author

+ Postmus, PE More by this author

Role:

Author

More authors...

Bibliographic Details

Publisher:: Elsevier
Journal:: Journal of Thoracic Oncology More from this journal
Volume:: 13
Issue:: 10
Pages:: S489-S489
Publication date:: 2018-10-22
Event title:: IASLC 19th World Conference on Lung Cancer
Event location:: Toronto, Canada
Event website:: https://wclc2018.iaslc.org/
Event start date:: 2018-09-23
Event end date:: 2018-09-26
DOI:: 10.1016/j.jtho.2018.08.626
EISSN:: 1556-1380
ISSN:: 1556-0864

Item Description

Language:: English
Keywords:: survival

durvalumab

nab-paclitaxel
Subtype:: Abstract
Pubs id:: 958268
Local pid:: pubs:958268
Deposit date:: 2020-06-08

Terms of use

Copyright holder:: Morgensztern et al.
Copyright date:: 2018
Rights statement:: Copyright © 2018 Published by Elsevier Inc.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP